(Total Views: 111)
Posted On: 01/03/2017 9:41:39 AM
Post# of 23083
$IDXG: Interpace Diagnostics will work w/ Evidence Street of the Blue Cross Blue Shield; provides co with the opportunity to support futher coverage determinations among Blue Cross Blue Shield for its molecular Thyroid and Pancreas tests
8:11 AM ET 1/3/17 | Briefing.com
Co entered in to an Agreement with the Blue Cross Blue Shield Association's Center for Clinical Effectiveness "Evidence Street", a program that, while not making coverage decisions, provides the Company with the opportunity to provide available evidence for its molecular Thyroid and Pancreas tests, to support further coverage determinations among Blue Cross Blue Shield and other health plans.
As part of the Agreement, Interpace will work with Evidence Street to develop the optimal ways for the Company to secure and preserve ongoing coverage for not only its currently marketed products but also for those tests in the pipeline being launched in the near future.Recall the 3 day, 1500% increase in its stock price from $0.12 to $1.98 from December 7-9 after the co announced Aetna coverage for its ThyraMir tests
8:11 AM ET 1/3/17 | Briefing.com
Co entered in to an Agreement with the Blue Cross Blue Shield Association's Center for Clinical Effectiveness "Evidence Street", a program that, while not making coverage decisions, provides the Company with the opportunity to provide available evidence for its molecular Thyroid and Pancreas tests, to support further coverage determinations among Blue Cross Blue Shield and other health plans.
As part of the Agreement, Interpace will work with Evidence Street to develop the optimal ways for the Company to secure and preserve ongoing coverage for not only its currently marketed products but also for those tests in the pipeline being launched in the near future.Recall the 3 day, 1500% increase in its stock price from $0.12 to $1.98 from December 7-9 after the co announced Aetna coverage for its ThyraMir tests
(0)
(0)
